With its technology showing promising results for spinal cord injuries, NurExone Biologic is making significant progress toward becoming a market leader in exosome-based treatment. Read our industry update below. Read More …
The demand for spinal cord injury (SCI) treatment has increased significantly because of the growing incidence of traumatic spinal cord injuries. According to a 2018 report from the United States National Library of Medicine, the prevalence of traumatic spinal cord injuries in low and middle-income countries was 8.72% per 100,000 people,
With its technology showing promising results for spinal cord injuries, NurExone Biologic is making significant progress toward becoming a market leader in exosome-based treatment. Read our industry update below. The demand for spinal cord injury (SCI) treatment has increased significantly because of the growing incidence of traumatic spinal cord injuries.
This time it’s our very own Dr. Irit Dolgopyat, PhD, R&D scientist at NurExone! Check out Irit’s interview about her role and work environment: 1. What R&D scientist do? Designing experiments that systematically characterize and improve the product. This role engages a great deal of strategic planning and creative problem solving.
“Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request,” said Dr. Lior Shaltiel, CEO of NurExone. “In addition to pursuing our regulatory objective, we are advancing other areas of our business, including securing
